Clinical Trials
35 trialsA Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
ALT-101
Allterum Therapeutics, Inc
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
MK-1045-002
MSD R&D (China) Co., Ltd.
MOMENTUM
AstraZeneca
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
ALLight
AstraZeneca
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Pharma Group Inc.
Study of Out of Specification for Tisagenlecleucel
Novartis
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
cAMeLot-1
Janssen Research & Development, LLC
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
AUGMENT-101
Syndax Pharmaceuticals
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
TENACITY-01
BIOHENG THERAPEUTICS US LLC
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx, Inc.
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
LONGSAFE
Miltenyi Biomedicine GmbH
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
CytoCares Inc
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Fresenius Kabi
HOPE
Ossium Health, Inc.
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
TriArm Therapeutics (Taiwan) Limited
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Novartis
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
CARLA
FamiCordTx
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Chongqing Precision Biotech Co., Ltd
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.